Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The impact of body mass index on Esophagectomy: perioperative and oncological outcomes.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026
Same author

Value-based health care definition and characteristics: an evidence-based approach.

Australian health review : a publication of the Australian Hospital Association·2025
Same author

Vaccine microarray patch self-administration: A preliminary study in adults 50 years of age and over.

Vaccine·2025
Same author

Vaccine microarray patch self-administration: An innovative approach to improve pandemic and routine vaccination rates.

Vaccine·2023
Same author

Topical hypertonic saline as a treatment for ocular and nasal hirudiniasis in a dog.

Australian veterinary journal·2023
Same author

Patient Characteristics and Variables Influencing Acute Medical Flow.

Acute medicine·2023
Same journal

Anticholinergic and central nervous system-active drug burdens and their associations with adverse in-hospital outcomes among older inpatients.

British journal of clinical pharmacology·2026
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

Interaction between debrisoquine and phenylephrine in man.

W Allum1, J Aminu, T H Bloomfield

  • 1Department of Pharmacology and Therapeutics, London Hospital Medical College, Turner Street, London.

British Journal of Clinical Pharmacology
|March 29, 2012
PubMed
Summary
This summary is machine-generated.

Debrisoquine potentiates the circulatory effects of phenylephrine, posing a potential hazard in some individuals. This interaction impacts blood pressure and pulse rate, requiring careful consideration in clinical practice.

Related Experiment Videos

Last Updated: May 23, 2026

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine
08:31

Optimized Griess Reaction for UV-Vis and Naked-eye Determination of Anti-malarial Primaquine

Published on: October 11, 2019

Area of Science:

  • Pharmacology
  • Cardiovascular Science
  • Clinical Research

Background:

  • Phenylephrine is a sympathomimetic amine used to increase blood pressure.
  • Debrisoquine is an antihypertensive agent that inhibits norepinephrine reuptake.

Purpose of the Study:

  • To investigate the interaction between phenylephrine and debrisoquine in human volunteers.
  • To assess the impact of debrisoquine on the circulatory effects of phenylephrine.

Main Methods:

  • Human volunteers (normal and hypertensive) participated in the study.
  • Phenylephrine was administered in single doses before, during, and after debrisoquine treatment.
  • Blood pressure, pulse rate, and pupil diameter were measured to assess circulatory effects.

Main Results:

  • Debrisoquine potentiated the circulatory effects of phenylephrine.
  • Marked potentiation was observed in a subset of subjects, indicating a potential hazard.
  • Limited insights were gained into debrisoquine's effects on baroreceptor responses and adrenergic mechanisms.

Conclusions:

  • The co-administration of phenylephrine and debrisoquine can lead to significant potentiation of phenylephrine's circulatory effects.
  • Clinicians should be aware of this interaction due to the potential for adverse cardiovascular events.
  • Further research is needed to fully elucidate the mechanisms underlying this drug interaction.